Alvotech: BofA Initiates Buy Rating as Biosimilar Launch Cycle Begins
FDA clears Reykjavik plant as biosimilar launches drive commercial growth.
Already have an account? Sign in.
FDA clears Reykjavik plant as biosimilar launches drive commercial growth.
Evercore lifts Expedia’s PT to $430 (from $375); Wedbush raises its target to $417 (from $334) following the Q2 earnings beat and raised guidance.
Visa flags Hims for high dispute rates on $39-to-$149 weight-loss memberships. Company faces fees, scrutiny, and must lower rate for 3 months.
The agreement does not specify how the proceeds would be used.